Qlt
As of the edition of 20 October 2026, Qlt runs 9 drugs, 6 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Qlt was renamed in 2016.
The records place 2 company names in this family.
- Aegerion Pharmaceuticals, Inc.: acquired in 2016; successor QLT Inc.
- QLT Inc.: renamed in 2016
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Leuprolide | Ended 2026 (exclusivity) | 1 |
| Dapsone | none listed | 0 |
| Verteporfin | none listed | 0 |
| Metreleptin | Ended 2026 (computed from the first US licence) | 0 |
| Porfimer sodium | none listed | 0 |
| Lomitapide | Ends 2029 (exclusivity) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| ABCB1 ATP-dependent translocase ABCB1 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Qlt needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 9 trials led
- Nutrition and metabolism: 8 trials led
- Eye: 3 trials led